Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer
- PMID: 37207653
- DOI: 10.1016/j.ccell.2023.04.013
Hot on the trail in the TME: Clues from a trilogy of checkpoint inhibitor trials in nasopharyngeal cancer
Abstract
In this issue of Cancer Cell, Yang et al. report the third in a series of phase III trials that demonstrates the survival benefit of combining a PD-1 inhibitor with chemotherapy in nasopharyngeal cancer. A gene expression analysis identifies "hot" and "cold" tumor signatures with prognostic and predictive significance.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests B.B.Y.M. is on the advisory board of Beigene, Singapore and a consultant for Alentis and Viracta Therapeutics. B.B.Y.M. received research grants from Bristol-Myers Squibb (BMS) and Merck Sharp & Dohme (MSD). Q.T.L. serves as an unpaid member of the Head and Neck Scientific Advisory Committee for Merck Research Laboratory.
Comment on
-
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309).Cancer Cell. 2023 Jun 12;41(6):1061-1072.e4. doi: 10.1016/j.ccell.2023.04.014. Epub 2023 May 18. Cancer Cell. 2023. PMID: 37207654 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
